Cardiology clinical research

BalanceD-HF is a clinical research study investigating whether two medicines working together are better at protecting heart and kidney health than one on its own.

Because HF and impaired kidney function are so closely linked, it’s important that we find new treatments that can effectively manage both conditions together. This is why we are looking at whether two study treatments (balcinrenone + dapagliflozin), working together, may help to protect your heart and kidney health at the same time, and more effectively than dapagliflozin on its own.

If you are interested in taking part in BalanceD-HF, please speak to your doctor or a member of the study team. They will be able to give you more information and help you decide what is best for you

Have you considered participating in a clinical study to learn more about your heart disease and living healthily?

If you have been diagnosed with heart failure and inflammation, this study may be for you. You may want to consider participating in the HERMES study evaluating if the study medicine can treat inflammation and show a benefit on heart failure.

Join HERMES in a journey of up to 4 years, with expert care, where your health is at the centre.

Speak with your doctor or nurse today: rduh.prcexeter@nhs.net

01392 406289

This study is sponsored and funded by Novo Nordisk

The Librexia Acute Coronary Syndrome (ACS) study is for adults who have had a heart attack in the past seven days who are at risk of having another heart attack or stroke, or of developing blood clots.

The main goal of the Librexia study is to see if the study medication is effective in reducing the risk of a future heart attack or other cardiac events, such as a blood clot somewhere in the body, or a stroke.

The study will recruit approx. 16,000 participants around the world, and is looking for adults who have had a heart attack in the past 7 days and are at risk of having another one despite receiving the standard of care for heart attack provision.

About 1 in 5 people who have a heart attack will go on to have a second one within 5 years. Some medications given after a heart attack, while important to take, may increase the risk of bleeding. The Librexia ACS study is looking to see if the study medication may provide a new treatment option that may help decrease the chance of having another heart attack, developing a blood clot, or having a stroke without causing a significant increase in bleeding.

If you, or someone you care for, are interested in learning more, speak to the study team: rduh.prcexeter@nhs.net 

01392 406289

The POSEIDON study looks at how common inflammation is in patients with both atherosclerotic cardiovascular disease and heart failure, as inflammation can make both conditions worse by damaging the heart and blood vessels.

The study is using blood tests to find biomarkers to understand inflammation in heart disease, heart failure, and also other conditions such as liver disease and kidney disease.

Get in touch with the study team to learn more: rduh.prcexeter@nhs.net

01392 406289

The MK-0616 research study is testing a study drug in adults with raised cholesterol who are at high risk of cardiovascular events associated with high cholesterol. Cardiovascular events cause serious illnesses, death, or health emergencies, and include heart attack, stroke and other complications.

The study is investigating whether an investigational medicine is effective at reducing the risk of majory cardiovascular events in high-risk individuals.

To be eligible, participants need to be:

· At least 18 years old or older

· Taking certain medications to treat high cholesterol

· At risk for major cardiovascular events

· Have raised levels of ‘bad cholesterol’ called LDL-C

Get in touch to learn more:

rduh.prcexeter@nhs.net 

01392 406289